Biotechnologies
ACCELERATING INNOVATIVE

We Acquire, Develop and Finance Undervalued Biomedical Assets

Slider

Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our technologies from incubation to monetization.

Q BioMed Announces Identification and Production of New Proprietary Drug Candidate for Pediatric Nonverbal Disorder

Q BioMed develops Proprietary Patentable Analog of QBM-001 ahead of scheduleNEW YORK, October 19, 2017 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that it has successfully developed a new and proprietary analog of...

Q BioMed Announces Favorable Amendment to Debenture Financing

Company and Yorkville Advisors have agreed to extend the maturity of the remaining debt balance for 12 months NEW YORK, October 12, 2017 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration Company, announced today that their funding partner...

Q BioMed Announces Development Partnership With Sphaera Pharma

Sphaera to Provide Proprietary Patentable Analogue of QBM-001 for IND filing NEW YORK, September 19, 2017 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new...

OUR GROWING PIPELINE MITIGATES RISK

Progress
0%

Topical eyedrops for glaucoma

PRECLINICAL

Image is not available
Progress
0%

PRECLINICAL

Chemotherapeutic for liver cancer

Image is not available
Progress
0%

Rare pediatric non-verbal Autism Spectrum Disorder

PRE IND 2/3

Image is not available
Progress
0%

COMMERCIALIZATION

Radio-pharmaceutical for metastatic cancer bone pain

Image is not available
Arrow
Arrow
Slider

OUR PORTFOLIO

METASTATIC CANCER BONE PAIN
CHEMOTHERAPUTIC FOR LIVER CANCER
RARE PEDIATRIC NON-VERBAL DISORDER
TOPICAL EYEDROPS FOR GLAUCOMA & IOP

THE RIGHT
FIRM

Focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.

THE RIGHT
SOLUTION

Our team assists companies by utilizing our strategic partners and network of experts to provide public market access for private company assets.  80% of biomedical start ups lack capital and resources to transition from incubation to development and beyond.

THE RIGHT
STRATEGY

Q expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.

Copyright © 2017 Q BioMed, Inc. All Rights Reserved

 

 

CONTACT

501 Madison Ave, 14th Floor
New York, NY 10022 USA
P: +1 888 357 2435
E: info@qbiomed.com